Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Antibody levels after COVID-19 vaccination inversely linked to body weight
May 23, 2022
An inverse correlation was sustained for up to six months following two doses of BNT162b2 (Pfizer–BioNTech) in a small cohort of healthy young and middle-aged adults.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Homologous, heterologous COVID-19 boosters are immunogenic
Feb 07, 2022
Antibody neutralizing titers against SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations.
COVID-19 certification mandates may increase vaccine uptake
Dec 22, 2021
Country-specific information, such as prior vaccination uptake and vaccine hesitancy, may influence the effect of COVID-19 certification mandates.
COVID-19 vaccines not tied to immune-mediated neurological events
Mar 21, 2022
But increased risks for Bell palsy, encephalomyelitis and Guillain-Barré syndrome were observed following SARS-CoV-2 infection.
COVID-19 vaccines prevent hospitalizations in high-risk populations
Sep 16, 2021
Vaccine effectiveness was 81 to 95% for adults aged 85 years and older, those with chronic medical conditions, and Black or Hispanic adults.
Breakthrough SARS-CoV-2 infections ID’d in fully vaccinated
Aug 02, 2021
39 infections documented in 1,497 health care workers; 19 percent had persistent symptoms despite most cases being mild, asymptomatic
Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
48.3 percent of U.S. ≥16s have had at least one dose of COVID-19 vaccine
Jul 15, 2021
As of May 15, 2021, coverage was lower for non-Hispanic Blacks and Hispanics versus whites; higher for those at risk for severe COVID-19.